SBIR/STTR Research Award

Plasmonic Glycan Arrays for Highly Sensitive Detection of Glycan-binding Proteins

Award identifier b580fdb24318114fb3207ef7cf42cdc6ee0778105261657e1c4b8d018a469257Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$222,939

Program and phase

SBIR · Phase I

Award year

2020

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
VITAN-BIOTECH LLC
Proposal award date
2020-08-01
Contract end date
2021-07-31
UEI
ML5NLF9L1FP9
Solicitation number
PA19-272
Topic code
300

Research abstract

Project SummaryExploring the biological information content in glycans represents one of the current focuses of postgenomic research and technology development. Glycan-based high throughput assays (e.g. glycan microarrays) hold great promise for the rapid analysis of carbohydrate binding proteins (CBPs), elucidation of CBP biology, and the development of diagnostics, vaccines, and therapeutics for a number of diseases, including cancer and neurological disorders. As the field of glycobiology grows, the important roles that glycans and glycoproteins play in health are becoming increasingly recognized. However, the “state- of-the-art” glycan arrays have several instinct limitations including poor dynamic range, poor sensitivity, and inability to easily interrogate multiple glycan-protein interactions simultaneously in complex samples. Because protein–glycan interactions are typically of low affinity, and many CBPs and auto-anti-glycan antibodies in clinical samples are generally in the range of fg/mL to pg/mL, the detection sensitivity of current glycan arrays is unable to reach the clinical threshold of many CBPs and auto-anti-glycan antibody biomarkers, especially in the early stages of the diseases when their concentrations in clinical samples very low. The goal of this project is to applied nanotechnology to overcome the major limitations of poor sensitivity and dynamic ranges of current glycan microarrays. We aim to develop and commercialize multi-plasmonic resonant photon enhanced fluorescent (MPREF) glycan array for glycomic research. With this project, we expect to develop ready-to-use products of: 1) the MPREF system include the components of plasmonic substrate and plasmonic fluorophores which will be marketed as glycan array kit, 2) a validated model MPREF glycan array containing 50+ Glycosaminoglycans.Project Narrative Protein–glycan recognition events are central to many biological processes. The goal of this project is to applied nanotechnology to overcome the major limitations of poor sensitivity and dynamic ranges of current glycan microarrays for studying the glycan- protein interactions.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

9 SBIR/STTR records share this UEI (2015–2024). Reported award amounts total $1,791,537. Reported amounts are not federal obligations.

Phases: Phase I

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.